Drug for treating nonalcoholic fatty liver disease and application of drug

Abstract

The invention relates to a drug for treating a nonalcoholic fatty liver disease. The drug comprises an effective quantity of a compound with the structural formula, pharmaceutically-acceptable salt and a pharmaceutically-acceptable carrier. R1 is H and halogen. R2 is independently selected from H, (1-6C)alkyl, (3-6C)naphthenic base, (2-7C)heterocyclic alkyl, (1-6C)alkyl amidogen, bi[(1-6C)alkyl]amidogen, (2-7C)heterocyclic alkyl amidogen and (3-6C)naphthenic base amidogen, and each kind is optionally replaced by one or more groups selected from (1-2C)alkyl, fluorine, hydroxyl and (1-2C)alkoxy. R3 is independently selected from H, halogen, (1-3C)alkyl, (1-2C)alkoxy, hydroxy(1-2C)alkyl, (3-4C)naphthenic base, (2-3C)alkenyl and cyano group. The drug can optimize various biochemical criterions in serum and has no toxic action on the liver.

Description

technical field [0001] The invention relates to the field of medicine, in particular, the invention relates to a medicine for treating non-alcoholic fatty liver and its application. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) refers to the clinicopathological syndrome characterized by diffuse hepatic bullous steatosis caused by alcohol and other definite liver damage factors, including simple fat Liver and its evolution steatohepatitis (NASH) and cirrhosis. In recent years, with the improvement of living standards and changes in lifestyles, the incidence of non-alcoholic fatty liver has been increasing. Some studies have shown that the prevalence of NAFLD in the general population of the United States, Western Europe, and Japan is 10% to 24%, while obesity The prevalence of NAFLD is as high as 57.5% to 74%. NAFLD will be the liver disease with the highest incidence in the future, and the treatment of NAFLD will be a challenge for hepatologists in...

AI Technical Summary

Problems solved by technology

Metformin is an insulin sensitizer, which can reduce the levels of plasma free fatty acids and plasma triglycerides by improving the glucose tolerance and hyperinsulinemia of patients, but it has obvious side effects and is very irritating to the gastrointestinal tract. Elderly patients are at risk for lactic acidosis

Therefore, there is still a lack of safe, effective, and effective drugs for the treatment of non-alcoholic fatty liver. It is very necessary to find drugs that can protect the liver, lower blood lipids, and resist fatty liver.

Images